Skip to main content
OpenTrials
Completed

NCT Number: NCT06263192

Pregnancy Prediction Using Anti-Müllerian Hormone in Intrauterine Insemination Cycles

The goal of this study is to compare the cumulative pregnancy rates after 4 artificial inseminations with donor (IAD) in non-sterile women with plasma AMH levels > and < 1.1 ng/mL.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–39 year

Sex eligibility

Female

Study type

Observational

Primary location

Fertty International

Barcelona, 08010, Spain

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • IUI cycles with sperm donors either due to severe oligoasthenoteratozoospermia in the partner (defined as a motile sperm count (MSC) < 5 million in the ejaculate) or for social reasons, with up to 4 attempts accounted for.

Exclusion criteria

  • BMI >30
  • Infertility due to bilateral tubal factor
  • Endometriosis grade II-IV.

Treatment and study plan

Intrauterine Insemination

Procedure

Intrauterine insemination with sperm donors

Primary outcomes

  1. Cummulative pregnancy rate

    Time frame: 36 months

    Pregnancy rate after 4 cycles of IUI

Sponsors and collaborators

Lead sponsor

Jose Antonio Moreno

Other

Collaborators

  • Universitat Autonoma de Barcelona

Registry information

Official study title

Pregnancy Prediction in Non-sterile Patients After 4 Intrauterine Inseminations With Donor Using Anti-Müllerian Hormone

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Feb 16, 2024
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.